The BIRD Foundation just approved another milestone payment for iTOL-102, our #Type1Diabetes cell therapy with Ajith. Another step closer to the clinic — and a potential cure, without life-long immunosuppression. #Biotech #CellTherapy finance.yahoo.com/news/nls-pharm…

🌏 Kadimastem secures Hong Kong patent for its IsletRx #technology—adding to U.S., Europe & India. With >700k adults living w/ #diabetes in HK, this milestone strengthens our global IP and patient mission. finance.yahoo.com/news/nls-pharm… 💡

Big milestone before our merger with NLS Pharmaceutics! The U.S. Securities and Exchange Commission has declared effective our Form F-4. The new company, NewCelX, will advance cell therapies for #ALS & #Diabetes alongside small-molecule CNS treatments. #Biotech #MergersAndAcquisitions finance.yahoo.com/news/kadimaste…

Nearly half of people with #diabetes don’t know they have it (via CNN The Lancet ). At @KadimastemLTD, we’re working to change the future of diabetes care with our IsletRx cell therapy program. 📖 Read more: uk.news.yahoo.com/nearly-50-peop… #DiabetesAwareness #CellTherapy

Milestone reached 🎉 NLS Pharmaceutics shareholders approved the #merger with Kadimastem → clearing the way for NewCelX Ltd. (Nasdaq: NCEL). Together we’ll advance cell therapies for ALS & diabetes + CNS drug programs. #biotech finance.yahoo.com/news/nls-pharm…

We’re proud to announce Nasdaq approval for our merger with @NLSPharmaceutics! 🎉 The merger will close Oct 30, 2025, creating NewCelX (Nasdaq: NCEL) — a next-generation biotech advancing cell & CNS therapies for #ALS and #diabetes. #Nasdaq #biotech finance.yahoo.com/news/nls-kadim…

We’re thrilled to announce our collaboration with TargetGene Biotechnologies! Together, we’ll develop next-gen gene-edited cell therapies for ALS, diabetes & more. 🧬 Learn more ➡️finance.yahoo.com/news/nls-pharm… #Kadimastem #TargetGene #CellTherapy #GeneEditing #ALS #Diabetes #Biotech

The BIRD Foundation will continue to support our ITOL-102 Diabetes cell-therapy program with @iToleranceBio — now advancing under NewCelX Ltd. #CellTherapy #Diabetes finance.yahoo.com/news/nls-pharm…